ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Clinical Supply Planning Lead at Revolution Medicines - ApplyBlast

Clinical Supply Planning Lead

Revolution Medicines

25 days ago

3.5 on Glassdoor

Redwood City, California, United States

Hybrid

Full Time

Senior

1 applicant

View Job Listing

Apply to 100+ jobs

About this role

This role leads end-to-end clinical supply planning for assigned oncology programs, ensuring global clinical demand is accurately reflected in supply systems and strategies. The position involves developing forecasts, managing inventory, and driving process standardization to support clinical studies from start-up through closeout. The ideal candidate will collaborate with cross-functional teams to mitigate supply risks and maintain continuity of materials.

Responsibilities

Lead end-to-end clinical supply planning for global clinical programs and studies
Develop demand forecasts and scenario models based on enrollment and dosing assumptions
Establish inventory and safety-stock strategies to minimize waste and expiry risk

Skills

Qualifications

Bachelor's degree in Supply Chain, Life Sciences, Engineering, Business, or a related discipline

About Revolution Medicines

revmed.com

Headquarters

Redwood City, California, United States

Company Size

201-500 employees

Founded

2014

View Profile

Revolution Medicines (RevMed) is a biopharmaceutical company dedicated to discovering, developing, and delivering novel targeted medicines for patients with cancer. Their mission focuses specifically on "revolutionizing treatment for patients with RAS‑addicted cancers" through precision-targeted therapies. The company emphasizes a science-driven, end-to-end approach from discovery to delivery. RevMed brands its team as "Revolutionaries" committed to transforming outcomes for people with RAS‑driven tumors.